A first preclinical study by Dzama et al. demonstrated that Menin inhibition targets FLT3 mutations transcriptionally in NPM1‐mutated and KMT2A‐rearranged leukemias and that combined Menin‐ and FLT3‐inhibition is synergistically active in these leukemia subtypes with concurrent FLT3 mutation. This evidence concerns the gene FLT3 and leukemia.